Planegg/Martinsried, October 2, 2024. Medigene AG (Medigene or the “Company”, FSE: MDG1, Prime Standard), an oncology platform company focused on the research and development of T cell receptor (TCR)-guided therapies for the treatment of cancer, will present a poster at the American Society of Gene & Cell Therapy (ASGCT) to be held October 16-17, 2024 in Philadelphia, PA in the US. In addition, the Company will host an R&D Event on Medigene’s optimal 3S (specific, sensitive, and safe) TCRs for TCR-guided precision immunotherapies on Thursday, October 10, 2024, at 4.30 pm CEST / 10:30 am ET.

ASGCT 2024
https://www.asgct.org/events/2024-advancing-gene-and-cell-therapies-for-cancer
Location: Wyndham Philadelphia Historic District, Philadelphia, PA
Date: October 16-17, 2024

The full abstract is now available on the ASGCT website: https://www.asgct.org/global/documents/abstracts/advancing-publication-v1.aspx

Details of the poster presentations are as follows:

Abstract and Title: “Seamless Integration of a Universal Epitope into Recombinant TCRs for Tagging and Tracking of TCR-T Cells Expressing 3S TCRs.”
Authors: Dolores Schendel, Kanuj Mishra, Justyna Ogonek, Anne-Wiebe Mohr, Doris Brechtefeld, Kathrin Mutze, Barbara L?sch
ProgramID: 31
Date and time: Wednesday, October 16, Poster Hall 2, Betsy Ross Ballroom, poster session from 5:30 – 6:45 p.m, poster will be on display from 8 a.m. – 6:45 p.m

The poster will showcase the Company's newly introduced technology, UniTope & TraCR, an innovative combination of universal TCR tagging and tracking. This system is designed to significantly enhance the precision and efficiency of T cell receptor identification and monitoring, offering remarkable capabilities for immunotherapy research and clinical applications.

Invite to the Company’s R&D event on October 10, 2024
Medigene will host an R&D Event on Thursday, October 10, 2024, at 4.30 p.m. CEST / 10:30 a.m. ET. A live Q&A session will follow the formal presentations and discussions.

Management will discuss the advantages of the Company’s 3S TCRs across various modalities, including TCR-T, TCR-TCE, and TCR-NK therapies. Principal Investigator of the EPITOME1015-I trial, Dr. David B. Zhen, MD, Associate Professor at both the Fred Hutchinson Cancer Center and the University of Washington School of Medicine, will provide an overview of the lead program, MDG1015, highlighting its innovative approach to addressing unmet needs in solid tumor treatment. Additionally, Medigene’s proprietary End-to-End Platform and its modular approach to generating TCR-guided modalities will be presented, including the latest advancements.